# Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax

> **NCT02083068** · PHASE2 · COMPLETED · sponsor: **Malaria Vaccine and Drug Development Center** · enrollment: 32 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** Vaccine PvCS N+C+R
- **BIOLOGICAL:** Vaccine PvCS N+C
- **BIOLOGICAL:** SSN Montanide ISA-51

## Key facts

- **NCT ID:** NCT02083068
- **Lead sponsor:** Malaria Vaccine and Drug Development Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-09
- **Final completion:** 2017-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02083068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02083068, "Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02083068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*